# US 2003/0216301 A1 · Thrombin inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216301 A1
- Document ID: US20030216301A1
- Status: Published application
- Kind: A1
- Application number: 10/427,435
- Filed: 2003-05-01
- Published: 2003-11-20
- Earliest claimed: 2002-05-02
- Assignees: Merk & Co., Inc.
- Inventors: James C. Barrow; Philippe G. Nantermet; Harold G. Selnick
- Web page: https://patentgrep.com/patent/US20030216301A1

## CPC

- C07K 5/12: Cyclic peptides {with only normal peptide bonds in the ring}
- A61K 38/55: Protease inhibitors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1 or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of the general formula
14
and pharmaceutically acceptable salts thereof, wherein
n is 0, 1,2 or 3;
X is hydrogen, halogen or C1-4 alkyl;
Y is a bond or —CH(R)—;
W is a bond or —(C(R4)(R5))1-5;
R and R1 are independently selected from the group consisting of hydrogen, C1-4 alkyl, cycloC3-7alkyl, aryl or a 5- to 7-membered heterocycle; and
R2, R3, R4, and R5, in each occurrence, are independently selected from the group consisting of hydrogen and C1-4 alkyl.

### Claim 2 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, where n is 1.

### Claim 3 (depends on 2)

A compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is cyclohexyl, pyridyl, methyl or phenyl, and R is hydrogen, phenyl or cyclohexyl.

### Claim 4 (depends on 3)

A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein X is Cl.

### Claim 5 (depends on 4)

A compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are independently selected rom the group consisting of hydrogen, —CH3 and —CH2CH3.

### Claim 6 (depends on 5)

A compound of claim 5, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
15 16

### Claim 7 (depends on 1)

A composition for inhibiting thrombus formation in blood comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method for inhibiting thrombus formation in a pateient comprising administering to the patient a compound of claim 1.

### Claim 9 (depends on 1)

A method for inhibiting formation of blood platelet aggregates in a patient comprising administering to the patient a compound of claim 1.

### Claim 10 (depends on 1)

The use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.

### Claim 11 (depends on 1)

A method for treating or preventing venous thromboembolism and pulmonary embolism in a mammal comprising administering to the mammal a compound of claim 1.

### Claim 12 (depends on 1)

A method for treating or preventing deep vein thrombosis in a mammal comprising administering to the mammal a compound of claim 1.

### Claim 13 (depends on 1)

A method for treating or preventing thromboembolic stroke in humans and other mammals comprising administering to the mammal a compound of claim 1.
